- Investing.com
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company’s Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Competitive Landscape | Analyst price targets range from $200 to $236, reflecting optimism amid potential challenges from new market entrants expected by late 2025 |
Financial Momentum | Delve into Insulet's robust financial performance, with Q3 2024 sales of $543.9 million exceeding estimates and EPS beating consensus by 13 cents |
Market Expansion | Explore Insulet's entry into the vast, underpenetrated Type 2 diabetes market, potentially reaching 6 million new patients in the United States alone |
Tubeless Innovation | Insulet's Omnipod 5, now FDA-cleared for both Type 1 and Type 2 diabetes, positions the company as a leader in automated insulin delivery systems |
Metrics to compare | PODD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPODDPeersSector | |
---|---|---|---|---|
P/E Ratio | 47.4x | −3.9x | −0.6x | |
PEG Ratio | 0.20 | 0.02 | 0.00 | |
Price / Book | 17.8x | 1.3x | 2.6x | |
Price / LTM Sales | 10.1x | 2.8x | 3.1x | |
Upside (Analyst Target) | 5.5% | 88.5% | 52.8% | |
Fair Value Upside | Unlock | 15.7% | 8.4% | Unlock |